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Abstract: Plants of the Apocynaceae family have been traditionally used in the treatment of 
age-related brain disorders. Rauvolfia reflexa, a member of the family, has been used as an 
antidote for poisons and to treat malaria. The dichloromethane, ethanol and methanol extracts 
from the leaves of Rauvolfia reflexa showed potential acetylcholinesterase  (AChE) and 
butyrylcholinesterase (BChE) inhibitory activities, with IC50 values in the 8.49 to   
52.23 g/mL range. Further cholinesterase inhibitory-guided isolation of these extracts afforded 
four bioactive compounds, namely: (E)-3-(3,4,5-trimethoxyphenyl)acrylic acid (1), (E)-methyl  
3-(4-hydroxy-3,5-dimethoxyphenyl) acrylate (2), 17-methoxycarbonyl-14-heptadecaenyl-4-
hydroxy-3-methoxycinnamate (3) and 1,2,3,4-tetrahydro-1-oxo-β-carboline (4). The isolated 
compounds showed moderate cholinesterase inhibitory activity compared to the reference 
standard, physostigmine. Compounds 1 and 2 showed the highest inhibitory activity against 
AChE (IC50 = 60.17 µM) and BChE (IC50 = 61.72 µM), respectively. Despite having similar 
molecular weight, compounds 1 and 2 were structurally different according to their chemical 
substitution patterns, leading to their different enzyme inhibition selectivity. Compound 2 was 
more selective against BChE, whereas compound 1 was a selective inhibitor of AChE. 
Molecular docking revealed that both compounds 1 and 2 were inserted, but not deeply 
into the active site of the cholinesterase enzymes. 
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1. Introduction 
Alzheimer’s disease (AD) is the leading cause of dementia among older people [1]. It is a chronic 
and progressive neurodegenerative disease characterized neuropathologically by the extracellular 
deposition of β-amyloid aggregates and intraneuronal neurofibrillary tangles. Neuronal loss at the 
affected regions causes deficit in production of the neurotransmitter acetylcholine, leading to cortical 
cholinergic dysfunction [2]. 
Based on the cholinergic hypothesis, acetylcholinesterase inhibitors were developed to sustain or 
enhance the acetylcholine levels. The crucial role of cholinesterases in neural transmission makes them 
a primary target of a large number of cholinesterase-inhibiting drugs and toxins [3], which toxins are 
useful for agricultural purposes and novel drugs that need to be prepared, although there is less interest 
in the new toxins [4]. Acetylcholinesterase inhibitors such as donepezil, rivastigmine and galantamine 
are currently still the best available pharmacotherapy for AD patients [5]. Natural products have 
contributed greatly as sources in drug discovery for Alzheimer’s disease. For examples, excellent 
acetylcholinesterase inhibitors such as physostigmine and galantamine have been isolated from 
Physostigma venenosum and Galanthus nivalis, respectively. Therefore, the search for new cholinesterase 
inhibitors from natural products is of great interest and ongoing in many parts of the World. 
Plants of the Apocynaceae family such as Tabernaemontana heterophylla Vahl were traditionally 
used in age related brain disorders by the Tukano Indians, in which a tea of the leaves is given for the 
old folks who are slow and forgetful. Similarly, Parahamcornia amapa was used against general 
debility in the Brazilian Amazon [6]. 
Rauvolfia reflexa is a member of the Apocynaceae family. Traditionally, it is believed to have 
strong antiplasmodial activity. In Tanzania, a decoction of the leaves is used to treat malaria [7]. To date, 
there are very few publications on this plant, mostly related to the isolation and characterization of its 
chemical constituents. In the present study, extracts and chemical constituents of Rauvolfia reflexa were 
evaluated for their potential cholinesterase inhibitory activity. Subsequently, a molecular docking study 
was undertaken to investigate the molecular interactions between the inhibitory compounds and enzymes. 
2. Results and Discussion 
2.1. Bioactivity-Guided Isolation 
Among the three extracts, the dichloromethane and ethanol ones exhibited good inhibitory activity 
against both enzymes, while the methanol extract showed moderate inhibitory activity against 
acetylcholinesterase. Thus, all three extracts were selected for further purification in the search for 
bioactive chemical constituents.  
The dichloromethane extract that showed the highest enzyme inhibitory activity against both AChE 
and BChE afforded compounds 1 (13 mg, 0.00065%, Figure 1) and 2 (19 mg, 0.00095%, Figure 1). Molecules 2013, 18  3781 
 
 
Compounds 3 (17 mg, 0.00085%, Figure 1) and 4 (12 mg, 0.0006%, Figure 1) were isolated from the 
ethanolic and methanolic extracts, respectively (Figure 2). The structures of 1–4 were confirmed by 
comparison of their NMR, MS, UV and IR spectra with those reported previously [8–11]. The HMBC 
correlations of compounds 1–4 are given in Figure 2. 
Figure 1. Compounds isolated from leaves of R. reflexa. 
 
Figure 2. HMBC correlations of compounds 1 to 4. 
 
2.2. Cholinesterase Enzymes Inhibitory Activity 
Initial cholinesterase enzymes inhibitory activity of the extracts was evaluated at 50 μg/mL while 
for the isolated chemical constituents this was done at 10 μg/mL. Among the extracts, the 
dichloromethane extract had the highest enzyme inhibitory activity against both AChE and BChE, with 
inhibition values of 80.79% and 90.11%, respectively. The ethanol extract also showed good inhibitory 
activity of more than 50% against both enzymes, but methanol extract only showed more than 50% 
inhibition against AChE. 
Among the isolated chemical constituents, 2 had the highest enzyme inhibitory activity against 
BChE, with an inhibition value of 91.29%, while the other three compounds showed inhibitions of less 
than 50% against BChE. On the other hand, for AChE, 2–4 had similar inhibition values of 40.36%, 
41.05% and 41.27%, respectively. 
Table 1 summarizes the IC50 and selectivity index of the R. reflexa extracts. The IC50 values 
obtained were in agreement with the initial screening data. Dichloromethane crude extract was the Molecules 2013, 18  3782 
 
 
most active extract, with IC50 values of 14.65 μg/mL and 8.49 μg/mL against AChE and BChE, 
respectively. In the present study, dichloromethane and ethanolic extract of R. reflexa showed good 
enzyme inhibitory activity against both AChE and BChE, while methanolic extract had moderate 
activity against AChE. Both dichloromethane and ethanolic extracts were more selective towards 
BChE inhibition than AChE, in contrast to the methanol crude extract. 
Table 1. IC50 values of Rauvolfia reflexa extracts for inhibitory activities on cholinesterase enzymes. 
Extract 
AChE inhibition, IC50
(μg/mL) 
BChE inhibition, IC50
(μg/mL) 
Selectivity for 
AChE 
a BChE 
b
Dichloromethane  14.65 ± 0.32  8.49 ± 0.92  0.58  1.73 
Ethanol  38.40 ± 0.15  26.47 ± 2.05  0.79  1.26 
Methanol  52.23 ± 4.02  ND  -  - 
Data presented as Mean ± SD (n = 3); 
a Selectivity for AChE is defined as IC50(BChE)/IC50(AChE);  
b Selectivity for BChE is defined as IC50(AChE)/IC50(BChE). 
The IC50 values and selectivity index of the isolated chemical constituents and reference inhibitor, 
physostigmine are shown in Table 2. For BChE, the IC50 was only determined for 2 as the others had 
less than 50% inhibition at 10 μg/mL. However, its IC50 value was higher than the dichloromethane 
extract, indicating that the inhibitory activity of dichloromethane could be potentiated by other 
compounds present in the dichloromethane extract. The IC50 value of 2 against BChE was 61.72 μM, 
which was approximately 105 times less potent than physostigmine. 
Table 2. IC50 values of Rauvolfia reflexa chemical constituents for inhibitory activities on 
cholinesterase enzymes. 
Data presented as Mean ± SD (n = 3); 
a Selectivity for AChE is defined as IC50(BChE)/IC50(AChE);  
b Selectivity for BChE is defined as IC50(AChE)/IC50(BChE). 
For AChE inhibition at 10 μg/mL concentration, compounds 2–4 showed almost similar inhibitory 
activity, while compound 1 had a much lower inhibition. However, comparison of their IC50 values 
showed that compound 1 had the lowest IC50 among all the compounds. Its activity was moderate and 
on molar basis, it is approximately 354 times less potent than physostigmine. The inhibitory activities 
of compounds 1 and 4 against AChE were more potent than their respective extracts, dichloromethane 
and methanolic extracts, whereas the inhibitory activity of compound 3 was less potent than that of 
ethanolic extract. 
In general, compared to physostigmine, the four isolated compounds showed moderate AChE 
inhibitory activity, while only 2 had good inhibitory activity against BChE. Despite their moderate 
Compound 
AChE inhibition, IC50  BChE inhibition, IC50  Selectivity for 
μg/mL  μM  μg/mL  μM AChE 
a BChE 
b 
1  14.32 ± 0.82  60.17 ± 14.45  ND  -  -  - 
2  37.63 ± 1.42  158.06 ± 5.9  14.69 ± 1.22  61.72 ± 5.14  0.39  2.56 
3  48.99 ± 2.86  97.37 ± 5.64  ND  -  -  - 
4  15.52 ± 0.68  83.38 ± 3.67  ND  -  -  - 
Physostigmine 0.046  0.17  0.162  0.59  3.47  0.29 Molecules 2013, 18  3783 
 
 
activity, these compounds could serve as leads for synthesis of potential analogues with improved 
inhibitory activity. An interesting observation in the present study is the inhibitory activity between 
compounds 1 and 2. Both of them had the same molecular weight but structurally different by their 
chemical substitution. Compound 1 is an acid whereas compound 2 is an ester. Compound 2 was found 
to be much more active than compound 1 against BChE. In addition, the relative selectivity of 
compound 2 is more on BChE than AChE, whereas for compound 1, this is reversed.  
2.3. Molecular Docking of Bioactive Compounds 1 and 2 
Figures 3 and 4 show compounds 1 and 2 docked onto the TcAChE and BChE enzymes, 
respectively. For compound 1, the major bindings were π-π stacking, hydrogen bonding, and 
hydrophobic interactions. The aromatic ring of 1 strongly stacked against the aromatic moieties of side 
chain residues such as Tyr 334 and Phe 331. A hydrogen bond (2.1 Å) between the N-H moiety of the 
Phe 288 residue and the C=O moiety of compound 1 anchors the ligand to the acyl binding pocket site 
of the active site gorge. This ligand also shows hydrophobic interactions with Trp 84, Phe 330 at the 
choline binding site, Tyr 121 at a peripheral binding site and Phe 290 at the choline binding site.  
Figure 3. Compound 1 docked into the active site of TcAChE. 
 
When compound 2 is docked onto the BChE receptor, there were indications of hydrogen bonds, 
hydrophobic, mild polar interactions and π-π stacking. His 438 at the catalytic triad showed a strong  
π-π stacking interaction with the aromatic moiety of 2. Phe 329 at the choline binding site and Trp 231, 
Val 288 and Leu 286 at the peripheral anionic site showed hydrophobic interactions mainly with the 
methoxy moieties of the ligand. Ala 199 and Gly 116 at the oxyanion hole showed strong hydrogen 
bonds (2.28 and 2.02 Å) with the methoxy moiety of the ligand. These results indicate that the 
compounds 1 and 2 were inserted, but not deeply, into the active site cavity, which is commonly 
observed in drugs used for treatment of AD [12].  
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Figure 4. Compound 2 docked into active site of BChE. 
 
3. Experimental  
3.1. Plant Materials 
The plant materials (leaves) of Rauvolfia reflexa were collected from the Pergau Hydroelectric 
Station, Jeli, Kelantan, Malaysia in July 2009. The botanical identification was made by Mr. Teo 
Leong Eng, Faculty of Science, University of Malaya. A voucher specimen (KL 4900) was deposited 
at the Herbarium of Chemistry Department, Faculty of Science, University of Malaya. 
3.2. Enzymes and Chemicals 
Acetylthiocholine iodide (ATCl), acetylcholinesterase from electric eel (AChE), 5,5'-dithiobis[2-
nitrobenzoic acid] (DTNB), butyrylcholinesterase from equine serum (BChE), S-butyrylthiocholine 
chloride and physostigmine were purchased from Sigma Chemicals (St. Louis, MO, USA). All the 
other reagents used were of analytical grade. 
3.3. General Experimental Procedures 
TLC was performed on aluminum and glass plates pre-coated with silica gel 60 F254  
(Merck, Darmstadt, Germany). 
1H-NMR and 
13C-NMR spectra were determined in CDCl3 on a JEOL 
JNM-FX400 spectrometer (Tokyo, Japan), UV spectra were recorded on a Shimadzu UV-160A 
spectrophotometer (Kyoto, Japan) using MeOH as solvent. MS was obtained on an Agilent 6530 mass 
spectrometer (Santa Clara, CA, USA). The IR spectrum was measured on a Perkin-Elmer RX 1 
spectrometer (Waltham, MA, USA) for the 4,000–400 cm
−1 frequencies range.  
   Molecules 2013, 18  3785 
 
 
3.4. Preparation of Extract 
The dried leaves of R. reflexa (2 kg) were first defatted in n-hexane (2,000 mL) for 48 h. Then, the 
extract was filtered and dried on the rotary evaporator. The residue was sequentially re-extracted with 
dichloromethane (CH2Cl2, 2,000 mL, two times), ethanol (EtOH, 2,000 mL, two times) and methanol 
(MeOH, 2,000 mL, two times) and the resulting filtrates were dried under reduced pressure by a rotary 
evaporator at 40 °C to yield CH2Cl2 (15 g, 0.75% yield), EtOH (10 g, 0.50% yield) and MeOH (14 g, 
0.70% yield) extracts, respectively. 
3.5. Isolation and Characterization of Bioactive Compounds 
Dichloromethane extract (15 g) was chromatographed on a silica gel 60 column (40–63 μm particle 
size) and eluted sequentially with CH2Cl2/n-hexane/MeOH mixtures (80:10:10 → 0:0:100). Eluates 
were collected and those displaying similar Rf values on TLC were pooled to yield 18 fractions. 
Fraction 12 was subjected to a preparative silica gel TLC with a solvent system of CH2Cl2/MeOH 
(90:10) to yield 1 (13 mg, 0.00065%) and (2, 19 mg, 0.00095%). 
Ethanolic extract (10 g) was chromatographed on a silica gel 60 column (40–63 μm particle size) 
and was eluted sequentially with CH2Cl2/n-hexane/EtOH mixtures (85:10:5 → 0:0:100). Eluates were 
collected and those displaying similar Rf values on TLC were pooled to yield 14 fractions. Fraction 9 
was subjected to a preparative silica gel TLC with a solvent system of CH2Cl2/EtOH (90:10) to yield 3 
(17 mg, 0.00085%). 
MeOH (14 g) extract was chromatographed on a LH-20 Sephadex column and was eluted 
sequentially with CHCL3/MeOH mixtures (80:20 → 0:100). Eluates were collected and those 
displaying similar Rf values on TLC were pooled to yield 22 fractions. Fraction 7 was further subjected 
to a preparative TLC on a reversed-phase silica gel with a solvent system of water/MeOH (30:70) to 
yield 4 (12 mg, 0.0006%). 
3.6. Characterization Data 
(E)-3-(3,4,5-Trimethoxyphenyl) acrylic acid (1): white amorphous solid; UV (MeOH) max 225, 307 
nm; IR (CHCl3) max 3338, 1731 cm
−1; ESIMS m/z 238.09 (M)
+(100), [calcd. for C12H14O5]; 
1H-NMR 
(CDCl3) 3.87 s, 3H, OCH3-3'), 3.87 (s, 3H, OCH3-4'), 3.87 (s, 3H, OCH3-5'), 5.50 (bs, 1H, OH-1), 
6.38 (d, J = 15.6 Hz, 1H, H-2), 6.74 (s, 1H, H-6'), 6.74 (s, 1H, H-2'), 7.58 (d, J = 15.6 Hz, 1H, H-3); 
13C-NMR (CDCl3): 53.4, 56.1, 60.4, 105.1, 106.5,118.6 122.7, 130.2, 142.6, 153.4, 153.4, 167.5. 
(E)-methyl 3-(4-hydroxy-3,5-dimethoxyphenyl) acrylate (2): white amorphous solid; UV (MeOH) max 
196, 273 and 328 nm; IR (CHCl3) max 3401, 1704 cm
−1; ESIMS m/z 238.09 (M)
+(100), [calcd. for 
C12H14O5]; 
1H-NMR (CDCl3)  3.79 (s, 3H, OCH3-1), 3.91 (s, 3H, OCH3-5'), 3.92 (s, 3H, OCH3-3'), 
5.80 (bs, 1H, OH-4'), 6.29 (d, J = 16.0 Hz, 1H, H-2), 6.77 (s, 1H, H-6'), 6.77 (s, 1H, H-2'), 7.59 (d,  
J = 16.0 Hz, 1H, H-3); 
13C-NMR (CDCl3): 51.7, 56.4, 56.4, 105.1, 105.1, 115.6, 125.9, 137.1, 145.2, 
147.2, 167.6. 
17-Methoxycarbonyl-14-heptadecaenyl-4-hydroxy-3-methoxy cinnamate (3): white amorphous solid; 
UV (MeOH) max 196, 273 and 328 nm; IR (CHCl3) max 3431, 1711 and 1738 cm
−1; ESIMS m/z 488.3 Molecules 2013, 18  3786 
 
 
(M)
+(100), [calcd. for C29H44O6]; 
1H NMR (400 MHz, CDCL3) 1.28–1.58 (s, 13H, '-13'), 2.10 
(d, J = 5.4 Hz 2H, H-14'), 2.31 (m, 2H, H-17'), 3.64 (s, 3H, OCH3-18'), 4.10 (t, J = 6.8 Hz, 2H, H-1'), 
5.32 (m, 1H, H-15'), 5.32 (m, 1H, H-16'), 5.90 (s,3H, OCH3-3''), 5.91 (bs, OH-4''), 6.27 (d, J = 16 Hz, 
1H, H-2), 6.90 (d, J  = 8.2 Hz, 1H, H-5''), 7.01 (s, 1H, H-2''), 7.10 (d, J  = 8.2 Hz, 1H,   
H-6''), 7.50 (d, J = 16 Hz, H-3); 
13C-NMR (100 MHz, CDCL3): 29.2–29.7, 29.8, 34.0, 51.5, 56.0, 64.6, 
114.7, 109.3, 115.7, 123.1, 127.1, 129.9, 130.1, 144.7, 146.8, 147.9, 167.4. 
1,2,3,4-Tetrahydro-1-oxo-β-carboline (4): brownish amorphous solid; [α]
24 
D : −16 (c 0.05, CHCl3); UV 
(MeOH) max 246, 302 nm; IR (CHCl3) max 3435, 1730 cm
−1; ESIMS m/z 186.08 (M)
+(100) [calcd. 
for C11H10N2O]; 
1H-NMR (CDCl3)  3.06 (t, J = 6.8, 14.2 Hz, 2H, H-6), 3.71 (dt, J = 2.7, 7.3 Hz, 2H, 
H-5), 5.76 (s, 1H, NH-4), 7.15 (dt, J = 0.9, 7.2 Hz, 1H, H-10), 7.31 (dt, J = 0.8, 6.9 Hz, 1H, H-11), 7.45 
(d, J = 8.2 Hz 1H, H-9), 7.58 (d, J = 8.2 Hz, 1H, H-12), 9.26 (s, 1H, NH-1); 
13C-NMR (CDCl3): 20.9, 
42.31, 112.5, 120.0, 120.4, 120.4, 125.3, 126.2, 126.2, 137.2, 163.1. 
3.7. Cholinesterase Enzymes Inhibitory Assay 
Cholinesterase enzymes inhibitory potential of test samples was evaluated using Ellman’s 
microplate assay following the method described by Ahmed and Gilani [13] with slight modifications. 
Physostigmine was used as positive control. Test samples and physostigmine were prepared in 
dimethyl sulfoxide (DMSO). The concentration of DMSO in final reaction mixture was 1%. At this 
concentration, DMSO has no inhibitory effect on both acetylcholinesterase and butyrylcholinesterase 
enzymes [14]. 
For acetylcholinesterase (AChE) inhibitory assay, 140 μL of 0.1 M sodium phosphate buffer (pH 8) 
was first added to a 96-wells microplate followed by 20 μL of test samples and 20 μL of 0.09 units/mL 
acetylcholinesterase enzyme. After 15 min of pre-incubation at 25 °C, 10 μL of 10 mM 5,5'-dithiobis 
(2-nitrobenzoic acid) was added into each well, followed by 10 μL of 14 mM acetylthiocholine iodide. 
After the initiation of enzymatic reaction, absorbance of the coloured end-product was measured for 15 min 
using Tecan Infinite 200 Pro Microplate Spectrophotometer (Männedorf, Switzerland) at 417 nm. 
For butyrylcholinesterase (BChE) inhibitory assay, the same procedures as described above were 
followed except for the use of enzyme and substrate, which were BChE from equine serum and   
S-butyrylthiocholine chloride, respectively. Each test was conducted in triplicate. Absorbencies of the 
test samples were corrected by subtracting the absorbance of their respective blank. A set of five 
concentrations was used to estimate the 50% inhibitory concentration (IC50). Percentage inhibition was 
calculated using the following formula: 
Percentage inhibition (%) =  
Absorbance of control - Absorbance of test sample
Absorbance of control
 × 100% 
3.8. Molecular Docking  
Among the isolated compounds, compounds 1, 2 had the highest inhibitory activities on AChE and 
BChE, respectively. Thus, both compounds were selected for further molecular docking evaluation to 
explore possible interactions between these compounds and the active sites of the enzymes. Molecular 
docking study was performed using Glide (version 5.7, Schrödinger, LLC, New York, NY, USA, 2011).  Molecules 2013, 18  3787 
 
 
Compounds 1 and 2 were docked onto the active site of TcAChE derived from three-dimensional 
structure of the enzyme complex with anti-Alzheimer’s drug, E2020 (Aricept™) (PDB ID: 1EVE) and 
to BChE derived from complex of the enzyme with Tabun analogue (PDB code: 2WIJ). Water 
molecules and hetero groups were deleted from receptor beyond the radius of 5 Å of reference ligand 
(E202 or Tabun), resulting protein structure refined and minimized by Protein Preparation Wizard 
using OPLS-2005 force field. The Receptor Grid Generation program were used to prepare AChE and 
BChE grids and all the ligands were optimized by the LigPrep program by using the OPLS-2005 force 
field to generate the lowest energy states of ligands. 
4. Conclusions  
In the present study, cholinesterase enzyme inhibitory activities of extracts and bioactive chemical 
constituents of Rauvolfia reflexa were investigated. Among the extracts, the dichloromethane and 
ethanol ones showed potential inhibitory activity against both AChE and BChE. The isolated chemical 
compounds showed moderate to weak inhibitory activity against both enzymes, compared to that of 
physostigmine, with compounds 1 and 2 having the most potent activity against AChE and BChE, 
respectively. These compounds were found to have contrasting cholinesterase enzymes inhibitory 
activities despite their similar molecular weight (differing in their chemical substitution patterns). 
Compound 2 showed selective inhibitory activity against BChE, whereas compound 1 was a more 
selective inhibitor of AChE. Both bioactive compounds were inserted into but did not fill the active 
site of the cholinesterase enzymes. 
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